Table 1. Clinical characteristics of patients on the TCIA cohort and independent testing cohort.
| Characteristic | TCIA cohort | Independent testing cohort | |||||
|---|---|---|---|---|---|---|---|
| GBM | LGG | P value | GBM | LGG | P value | ||
| Patients | 106/233 (45.5) | 127/233(54.5) | 105/334 (31.4) | 229/334 (68.6) | |||
| Age (year) | 58.7±13.6 | 46.0±13.8 | <0.001* | 44.3±13.3 | 37.5±11.6 | <0.001* | |
| Gender | 0.04* | <0.001* | |||||
| Woman | 41/106 (38.7) | 63/127 (49.6) | 35/105 (33.3) | 107/229 (46.7) | |||
| Man | 65/106 (61.3) | 64/127 (50.4) | 70/105 (66.7) | 122/229 (53.3) | |||
| Tumor grade | <0.001* | <0.001* | |||||
| WHO II | 0 (0.0) | 63 (49.6) | 0 (0.0) | 112 (48.9) | |||
| WHO III | 0 (0.0) | 64 (50.4) | 0 (0.0) | 117 (51.1) | |||
| WHO IV | 106 (100.0) | 0 (0.0) | 105 (100.0) | 0 (0.0) | |||
| 1p19q codeletion | <0.001* | 0.70 | |||||
| Codeletion | 0/106 (0.0) | 36/127 (28.3) | 5/105 (4.8) | 14/229 (6.1) | |||
| Wild type | 106/106 (100.0) | 91/127 (71.7) | 12/105 (11.4) | 31/229 (13.5) | |||
| Unknown | 0/106 (0.0) | 0/127 (0.0) | 88/105 (83.8) | 184/229 (80.4) | |||
| IDH mutation | 0.64 | <0.001* | |||||
| Mutation | 8/106 (7.5) | 103/127 (81.1) | 18/105 (17.1) | 110/229 (48.0) | |||
| Wild type | 98/106 (92.5) | 24/127 (18.9) | 46/105 (43.8) | 48/229 (21.0) | |||
| Unknown | 0/106 (0.0) | 0/127 (0.0) | 41/105 (39.1) | 71/229 (31.0) | |||
| Histology | <0.001* | <0.001* | |||||
| Astrocytoma | 0/106 (0.0) | 36/127 (28.3) | 0/105 (0.0) | 82/229 (35.8) | |||
| Oligoastrocytoma | 0/106 (0.0) | 32/127 (25.2) | 0/105 (0.0) | 83/229 (36.2) | |||
| Oligodendroglioma | 0/106 (0.0) | 59/127 (46.5) | 0/105 (0.0) | 44/229 (19.2) | |||
| Glioblastoma | 106/106 (100.0) | 0/127 (0.0) | 105/105 (100.0) | 0/229 (0.0) | |||
| Unknown | 0/106 (0.0) | 0/127 (0.0) | 0/105 (0.0) | 20/229 (8.8) | |||
Data in parentheses are percentages. * indicates significant difference.